- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Briquilimab, Placebo
- Drug · Other
- Lead sponsor
- Jasper Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–62
of 62
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Urticaria, Idiopathic
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Chronic Spontaneous Urticaria (CSU)
- Interventions
- Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Omalizumab Injection, Xolair Prefilled Syringe
- Drug
- Lead sponsor
- Kashiv BioSciences, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 11
- States / cities
- Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
- Conditions
- Chronic Urticaria
- Interventions
- TEV-45779, XOLAIR® Injection
- Combination Product
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ligelizumab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more
- Conditions
- Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
- Interventions
- THB335 Lower Dose, THB335 Higher Dose, Placebo
- Drug
- Lead sponsor
- Calixis Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 15
- States / cities
- Pasadena, California • Ventura, California • Walnut Creek, California + 12 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching Placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 44 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 40
- States / cities
- Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more
- Conditions
- Urticaria Chronic
- Interventions
- Placebo, 0.5 mg epinephrine, 1 mg epinephrine
- Drug
- Lead sponsor
- ARS Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Glenview, Illinois • Cincinnati, Ohio
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey